



Building a Better Future

ESG Presentation



Building a Better Future Through Our Mission

We are committed to addressing areas of significant unmet medical need through the development of innovative regenerative medicine therapies that extend and enhance the quality of human life.



Without our health, we have nothing

It is hard to argue against health being the most important of all environmental, social and governance (ESG) values. So we start by asking, what are some of the biggest threats to global health?



Strokes

Current treatments are largely ineffective unless administered within a few hours of the stroke—too late for most victims.

17M

people suffer a stroke every year



Acute Respiratory Distress Syndrome (ARDS)

ARDS is the leading cause of death among COVID-19 patients. ARDS treatments require extended and expensive hospital care, and patients frequently experience quality of life issues in the aftermath.

~500,000

people afflicted annually (in a non-pandemic year)



Trauma

Trauma is the leading cause of death and serious disability among Americans age <45. It is also the leading cause of life years lost before age 75 and a major source of disability for youth, the elderly and military personnel.

180,000

fatalities per year in the U.S.

Our MultiStem[®] cell therapy holds promise for each of these and more

This promise is real and near term. MultiStem is a patented regenerative medicine that has shown promise promoting tissue repair and healing in a variety of ways.

MultiStem is being evaluated in several clinical-stage programs, including ischemic stroke, ARDS and trauma (two of which are pivotal Phase 3 trials). This technology has received Fast Track and RMAT designations from the FDA (as well as similar designations in Europe and Japan). We are actively developing the manufacturing process for MultiStem in large scale bioreactors and gearing up for potential approval.

And this potential is free of many of the challenges other stem cell treatments have:



No fetal or embryonic stem cells used; only bone marrow from healthy consenting adults



Favorable and consistent tolerability data




Highly scalable




Easy to transport, store, and administer

And this is only the beginning. We have over 300 patents related to these technologies and are working with leading clinical experts, hospitals and research institutions, as well as other partners to develop MultiStem for additional indications.



Based on Proprietary MAPC Technology

Broad IP estate covering core technology, methods of production & areas of use



Promotes Healing and Tissue Repair

Works through multiple mechanisms of action



Administered Systemically or Locally

Off the shelf administration with no tissue matching or immune suppression required




Long Shelf Life

Consistent safety & tolerability profile, with > 8 years of stability data on cryogenically stored product

Advancing our robust pipeline towards commercialization

We have established a diverse portfolio of diseases and conditions for treatment in regenerative medicine, with an emphasis on treating critical care indications.



Our ability to help people (the S in ESG) extends beyond working to treat some of the most feared, most lethal, most expensive, and most widespread of medical conditions



We have a diverse global workforce and are led by a Board, 56% of whom (5 of 9) are diverse by race, ethnicity or gender, and led by a management team with similar diversity.



Our people are our brain trust.

We work to protect their well-being and creativity, and demonstrate our commitment via numerous health, wellness, retirement and other benefit programs, significant advancement and pay opportunities, several affinity groups, community outreach programs and active listening and feedback loops.



Working in a cutting-edge medical field helps us attract top talent. The best biotech recruiting tool is the quality of a company's therapies, a strong corporate culture and a unified mission to help patients and their families.

We have few environmental risks but take numerous opportunities to show environmental leadership



We run environmentally responsible laboratory waste collection, recycling and disposal programs.



We are ramping up our manufacturing and facilities capabilities using leading environmentally responsible and carbon footprint principles.



We encourage our employees to be environmental leaders. We have a strong and longstanding commitment to volunteering, philanthropic activities, employee wellness and education.



We have a strong governance structure that supports our leading scientific and development profile

Our governance profile is unusually advanced for a pre-commercial biotech of our size:



One class of voting shares (no dual class cap)



Annual director elections (no staggered board)



No super majority provisions or poison pill



Majority voting



Special meeting and written consent rights



Board and management team diverse by gender, race, ethnicity and national origin



Active Board refreshment process; five new non-management directors since 2018




Annual Board and key committee self-assessment review



Exemplary internal and external pay parity




Robust ethics and conflicts policies



A strong governance structure without strong leaders at the Board and management level is not enough. We have both.

Name	Title	Prior Experience
 <p>William (B.J.) Lehmann, JD</p>	<p>Interim CEO, President & COO</p>	   
 <p>Ivor Macleod, MBA, CPA</p>	<p>CFO</p>	   
 <p>John Harrington, PhD</p>	<p>EVP and CSO, Board member</p>	  
 <p>Manal Morsy, MD, PhD</p>	<p>SVP, Global Regulatory Affairs</p>	   
 <p>Maia Hansen, MBA, MS</p>	<p>SVP, Operations and Supply Chain</p>	   
 <p>Greg Liposky, MBA</p>	<p>SVP, Commercial Manufacturing</p>	   
 <p>Laura Campbell, CPA</p>	<p>SVP, Principal Accounting Officer</p>	 

Our Board of Directors

Name	Title	Professional Affiliations*	Educational & Policy Affiliations*
 Ismail Kola, PhD	Chairman <i>(Since February 2021; director since October 2010)</i>		
 John Harrington, PhD	Director <i>(Since founding in 1995)</i>		
 Hardy TS Kagimoto, MD	Director <i>(Since June 2018)</i>		
 Katherine Kalin, MBA	Independent Director <i>(Since November 2020)</i>		
 Lorin J. Randall, MBA	Independent Director <i>(Since September 2007)</i>		
 Baiju R. Shah, JD	Independent Director <i>(Since November 2020)</i>		
 Kenneth H. Traub	Director <i>(Since February 2021)</i>		
 Jane Wasman, JD	Independent Director <i>(Since November 2020)</i>		
 Jack L. Wyszomierski, MS	Independent Director <i>(Since June 2010)</i>		



Thank You